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Stroke is the fourth leading cause of death in the United States and affects nearly 800,000 individuals yearly. 1 Despite recent advances in stroke prevention and acute therapy, there are more than 6 million stroke survivors living with disability as a result of stroke. 1 Since the 1980s, progress in stroke treatment has focused on prevention and acute therapy. Only recently has attention turned toward applying robotics, stem cells, and braincomputer interfaces (BCIs) to foster brain repair and recovery.
Robotics
The development of robotic devices for rehabilitation purposes has grown steadily during the last decade, but the overall impact on rehabilitation care delivery remains modest. The potential applications of robots in stroke rehabilitation may be classified in various ways. The authors classify them as follows:
& Exercise training devices for neurologic disorders & Wearable powered braces for daily use & Range of motion/strength training devices for musculoskeletal disorders & Assistance with activities of daily living & Social/telepresence robots In this article, the authors will focus on the use of robots as exercise training devices, as this is the best studied rehabilitation application of these devices and also the most relevant to regenerative medicine.
Cell-based Therapy
Cell therapy is one approach to brain repair that is safe and effective in animal models of stroke. Stem cells migrate to the site of injury, survive, and differentiate. Cell therapy is attractive because of the multiple potential mechanisms for benefit in brain repair. Stem cells may differentiate into multiple cell types including neurons, astrocytes, and endothelial cells promoting both neurogenesis and angiogenesis. Secretion of growth factors, interleukins, or cytokines may enhance the local environment and promote axon growth or synaptogenesis. Suppression of immune responses to brain injury could also reduce the extent of infarction and improve outcomes. Some cell types are capable of integrating with the local environment possibly directly influencing brain function.
Brain-Computer Interfaces
BCI generally refers to directly accessing brain activity as a means to obtain control signal for control of devices or, potentially, to tap into neuroplasticity. Restoration of upper limb function is a top priority for individuals with stroke. Although initial work has not generally focused on stroke, BCI research has focused on the recovery of upper limb function. Sophisticated, motorized prostheses are being developed 2,3 that enable natural upper limb movement and have advanced sensing capabilities. These motorized prostheses can provide function comparable with that of an intact limb, but a high degree-offreedom (DOF) control interface is needed. Recent work has shown great success in achieving motor control in two subjects with paralysis.
In this article, the authors will review that success and discuss the implications of all three approaches for individuals with sequelae from stroke. In each area, the authors will review the conceptual basis for use of the therapy and barriers to broader clinical adoption. Finally, the authors will discuss how these three separate areas could work in concert to achieve maximum clinical improvement.
ROBOTIC REHABILITATION AT THE CROSSROADS
Although exercise training robots may be useful in a variety of disorders (e.g., cerebral palsy, traumatic brain injury, spinal cord injury), treatment of hemiparesis after stroke is the most widely studied application. 4 The reasons for this focus on stroke include the large number of people affected, the well-documented behavioral benefits, and cortical plasticity that occurs in response to exercise training after stroke. The relatively focal deficits that commonly leave stroke survivors capable and motivated to participate in robotic therapy.
Why use robots to deliver exercise therapy for stroke rehabilitation? Several arguments in their favor have been advanced. Among the most important is the potential for labor-saving allowing greater therapeutic productivity for therapists. Currently, most exercise therapies are delivered one-on-one by skilled therapists (chiefly physical and occupational therapists) at considerable cost. Developing devices that would allow delivery of the same amount of therapy with fewer staff, or greater amounts of therapy with the same personnel resources, provides potential economic and clinical benefits. Although the optimal amount of therapeutic exercise after stroke remains unknown, many stroke rehabilitation physicians and researchers believe that few stroke patients receive sufficient therapy presently to achieve optimal motor outcomes.
There are important economic barriers to achieving the productivity advantages that robots offer. The commercially available robots are expensive, with some costing several hundred thousand dollars. At the same time, these devices remain under rapid evolution, and the useful life of any specific device is likely to be relatively short. Moreover, many of these devices (especially the workstation devices) consume a substantial amount of spaceVan expensive resource that is often in short supply.
Robotic devices remain highly specialized and are limited in their ability to truly substitute for human therapy. For example, no currently available robot can assist patients with learning dressing tasks or with bathroom transfers. Thus, robots tend to be used to supplement, rather than substitute for, conventional therapy. Although adding robotic exercise to conventional therapy may be desirable therapeutically, the incremental costs are currently not reimbursable by insurance.
Robot-assisted therapy currently lacks specific reimbursement codes in the United States and is generally billed as standard physical therapy or occupational therapy. This adds the equipment costs of the robots to the cost of providing physical therapy or occupational therapy without providing any incremental revenue. This also contributes to the inability to substitute for conventional therapy, as robotic therapy that is not directly overseen by a therapist is not billable under existing rules.
Overcoming these economic barriers is challenging, but there are several strategies that might be used. One is to reduce the cost of robots through economies of scale so that the costs associated with their adoption are relatively minor in the overall process of rehabilitation. Another would be to move robotic therapy into the home environment, where patients require less supervision. This approach requires devices that are easier to use and also the development of less expensive devices. An alternative would be to develop robotic gyms, where one therapist supervises multiple individuals. 5 However, alterations to the payment system are needed to make this strategy economically advantageous.
Another putative advantage of robots is their ability to deliver a well-defined and reproducible form of exercise therapy. Human therapists vary from person-to-person and from session-to-session in the specific activities that constitute exercise therapy. This lack of standardized therapy makes it difficult to precisely compare different therapy techniques. In contrast, robots deliver exercise therapy based on their programming that varies only based on the patient's performance and as dictated by their algorithms. In principle, this ability to precisely control the therapy delivered by a robot should allow reliable studies to compare different treatment algorithms and optimize motor retraining. In practice, the small effect sizes seen for all motor therapies (both robotic and nonrobotic) in patients with chronically hemiparetic stroke make comparisons of different treatment algorithms challenging, unless large patient populations are studied.
Many robots can incorporate virtual reality or gaming scenarios to make exercises more interesting for the patient and to maintain a high level of patient motivation. Although existing commercial devices have not yet fully leveraged this approach, incorporation of more sophisticated and enjoyable games seems inevitable.
One potentially alluring aspect of rehabilitation robotics is more effective therapy than conventional human-delivered rehabilitation. The potential to deliver a more effective treatment algorithm has been hampered by the field's limited understanding of the optimal form, dosage, and timing of exercise therapy. The ability of robots to deliver greater numbers of repetitions than human therapists with greater consistency is appealing, but robotic therapies have not yet proven to be more effective than dose-matched human-delivered treatment. 6 Given that most available robotic devices are workstation devices that simulate functional tasks rather than allowing performance of actual tasks, it is important to explore the impact of interaction with actual objects in functional context on motor outcomes. The treatment algorithms currently embedded in robots lack the same degree of feedback and adjustment as a skilled human therapist. Although robots can be programed to provide motivating stimuli, they lack the nuanced ability of a human therapist to detect the user's emotional state, motivation, and effort and adjust therapeutic strategies accordingly.
Many robotic devices contain built-in measurement capabilities, providing an automated means of measuring various aspects of patient movement abilities. 7 These measures have been demonstrated to be sensitive to change in patients undergoing robot-aided rehabilitation 8 and to correlate with clinical measures. 8, 9 Although utility as a research tool is well established, it is not yet clear what role these measures might play in monitoring progress during routine clinical rehabilitative care.
Although each robot has a distinct design, there are common themes that allow classification of exercise robots into several broad categories.
Workstation: End-Effector Robots
These devices are designed to be used in a therapeutic environment (e.g., gym), and the user interacts with the device in this defined area. The primary means of exerting force on the user is through a single point of contact, typically at the distal part of the limb.
Workstation: Exoskeletal
Workstation robots can also be of exoskeletal design, where the device provides forces at multiple locations along the limb (Fig. 1 ).
Wearable Exoskeletal
Wearable exoskeletal robots are, in essence, powered orthoses (Fig. 2 ). These robots have the potential advantage of allowing interaction in varied environments and in a variety of activities. Conversely, unlike workstation robots, wearable robots do not generally incorporate virtual reality/gaming. Safety considerations can be complex for wearable devices, because of the less predictable and controlled environment and the risk of falls while using the device. An important aspect of wearable exoskeletal devices is that they can be used for exercise training purposes and/or as wearable powered braces for daily use. The use of such devices as powered braces to substitute for weak or paralyzed muscles is notably important for spinal cord injury but applicable to a number of other neurologic conditions as well.
CELL THERAPY

Cell Types
A variety of cell types have been used for cell therapy, and each has advantages and disadvantages (Table 1) . Neural stem cells include embryonic, fetal, and adult cells according to the source. These cells generate multiple cell types that may be beneficial in repairing ischemic injury when there is loss of brain parenchyma. Neural stem cells are easily expanded in cell culture allowing production of sufficient numbers for clinical applications. Embryonic stem cells may be more prone to tumor formation than cells of more committed lineage, and both embryonic-and fetal-derived cells are associated with ethical concerns.
Immortalized cells are transformed by an oncogene or isolated from primitive tumors. They avoid the issues surrounding fetal and embryonic tissue yet, like those cells, are easily expanded in cell culture. Because they must undergo some degree of differentiation before transplantation to prevent tumor formation, the cell types produced are more limited. Even with differentiation, there is concern about tumor formation given the origin of these cells.
Mesenchymal stem cells (MSCs) are most commonly used at present for cell therapy. These cells may be derived from the bone marrow, adipose tissue, umbilical cord blood, and dental pulp. They can be isolated from one or more donors and then expanded for clinical use (allogeneic) or isolated from a single patient and then given back to the same patient after sufficient expansion (autologous). MSCs only transiently survive when implanted in the brain or infused intravenously, and thus, the likely mechanism by which these cells improve neurologic function is a paracrine function with secretion of growth factors and other substances. Considerable preclinical data show improvement on a variety of functional tests and enhancement of neurogenesis, synaptogenesis, and angiogenesis. MSCs also alter the immune response after stroke possibly reducing the contribution of early inflammation to brain injury and impairment of recovery.
The mechanism of action for each cell type may differ depending on the time after stroke onset. In the first 24 hrs after stroke, neuroprotection is likely most important to prevent further cell loss and apoptosis in penumbral areas. In the early poststroke period, possibly up to 1 mo after stroke, there is active remodeling of the brain, and promoting angiogenesis, neurogenesis, and synapse formation may be desirable targets. Later, repair of established scar tissue might require scaffolds and multiple cell types capable of forming functioning new connections.
The optimal route of administration may also vary across cell types. Intravenous infusion of cells is most convenient and universally applicable. Cells must pass through the lungs, and larger stem cells may clump in passage through the small pulmonary arterioles causing pulmonary and systemic symptoms. Intravenous infusion also distributes cells to other organs besides the brain. Intra-arterial infusion bypasses the lungs but also could potentially occlude small brain vessels and must traverse the blood-brain barrier to reach the brain. Direct intraparenchymal injection assures that cells will reach the site of injury. Complications of stereotactic cell delivery are rare but include parenchymal hemorrhage, subdural hematoma, seizures, or infection.
Clinical Trials of Cell Therapy for Stroke
In 2000, Kondziolka et al. 10 published the first safety and feasibility trial of cell therapy for stroke. Patients 6 mosY6 yrs after stroke onset were treated by stereotactic infusion of immortalized cells into the basal ganglia. The NT2N cells were isolated from a teratocarcinoma and maintained in cell culture. After treatment with retinoic acid, these cells consistently differentiated into postmitotic neurons that, when implanted in animal models of stroke, formed synapses and axons resulting in improved performance on functional tests. In the first clinical study, 12 patients were treated with 2 or 6 million cells 7Y55 mos after stroke. One patient had a seizure likely related to the stereotactic procedure, and another experienced an unrelated brainstem stroke 6 mos after treatment. Two patients died during follow-up, one from a myocardial infarct and another because of pneumonia. In a subsequent phase 2 study of 14 patients, there were no complications directly related to the infused cells. 11 A seizure in one patient and an asymptomatic subdural was attributed to the stereotactic procedure. Improvement compared with baseline was observed in some clinical measures including the Stroke Impact Scale and Action Research Arm Test, but the significance of these changes in this small group of patients is uncertain. One patient died of a myocardial infarct 27 mos after cell implantation. In this patient, neuropathologic studies showed evidence of surviving transplanted neurons in the area of the graft, indicating that transplanted cells can survive at least 2 yrs after treatment 12 (Fig. 3) .
In the past few years, several additional trials of cell therapy have been published. 13Y17 Most used autologous MSCs infused either intravenously or, in one case, intra-arterially for middle cerebral artery territory strokes. All are relative small studies including 6Y16 patients receiving cell infusions. Time from stroke onset varies from 5Y9 days to 3Y12 mos after stroke. These studies all found adequate safety without any cell-related complications. Conclusions regarding efficacy are hazardous with such small numbers of patients, but in most studies, no significant clinical changes were observed. In one study, there was an increased rate of change of National Institutes of Health Stroke Scale after cell infusions, 14 and another found a trend toward improved outcomes after 3.5 yrs. 15 
BRAIN-COMPUTER INTERFACES
In discussing BCI, understanding a few concepts is key. One concept is the degree of freedom (DOF) of control. One DOF allows for control of a point moving back and forth along a line in space.
Two DOFs, or 2D, allow for movement along a plane, similar to controlling a computer cursor with a mouse. Three DOFs allow for reaching in 3-dimensional (3D) space. Addition DOFs allow for additional levels of control needed to perform complex tasks. A second concept is related to where the BCI signals are recorded. The least invasive source of BCI signals is electroencephalography. Unfortunately, because the electrical activity of the brain is filtered by the bone and soft tissue, electroencephalography only allows limited DOF control. The authors will therefore focus on two other methods of recording data. Electrocorticography (ECoG) records signals from the surface of the brain, thus recording from populations of neurons. Finally, microelectrode arrays (MEAs) penetrate into the brain for a short distance and record from individual neurons.
Later, the authors will describe techniques involved and results from two studies at the University of Pittsburgh that demonstrated high DOF control in subject with paralysis at the level of the spinal cord. After presenting this information, the authors will discuss the potential relation to stroke.
Motor Mapping for BCI Planning
Because electrode placement is important to success, the authors completed functional magnetic resonance imaging to map motor-related cortical activity as part of the presurgical planning. 18, 19 The first subject participated in the authors' ECoG BCI study and had C4 complete spinal cord injury. The second subject participated in the authors' MEA BCI study and had a multiple sclerosis variant that resulted in complete motor loss below the level of the neck but with intact sensation. During functional magnetic resonance imaging, the authors used a simple block design paradigm where subjects imagined performing single-joint movements along with a video. Participants imagined performing repeated joint movements to mimic the movement of a firstperson video of the same task. The goal of this mapping was to identify which areas of the motor cortex were active during attempted arm and hand movements to help direct the surgical placement of recording electrodes.
ECoG BCI and Somatotopy in the Sensorimotor Cortex
In the authors' ECoG study, 19 signals were recorded with a high-density 32-electrode grid over the hand and arm area of the left sensorimotor cortex. ECoG signals demonstrated modulation when the participant observed and simultaneously imagined right hand and arm movements although the participant was unable to generate overt movements. The most prominent modulation patterns were an increase in power for the gamma and high-gamma bands and a decrease in power for the sensorimotor rhythm (10Y30 Hz), both tightly coupled in time with movement. Attempted movements of the hand and elbow elicited distinct cortical activity patterns, with the centers of activation being lateral for attempted hand movement and medial for attempted elbow movement on the ECoG grid.
On the basis of the different cortical activation patterns for different imagined movements, the participant was able to volitionally modulate sensorimotor cortical activity to achieve high-fidelity real-time BCI control of 2D and 3D cursor movements. The subject reported that imagining specific movements, such as moving a videogame joystick, was more effective than just thinking about Bmoving his thumb.[ That motivated the authors to study the effect of goal-directed tasks for covert brain mapping. Using imagined movement to drive the computer cursor, the subject achieved a success rate of 87% for 176 trials in the last 2D cursor control session. By the end of training, the participant achieved 80% of success rate for 3D cursor control. On day 27, the participant controlled the 3D movement of a prosthetic arm successfully to hit physical targets and Bhigh-five[ members of the research team. The subjects commented that this was the first time that he reached out to another individual in 7 yrs. This demonstrates not only the potential use of an ECoG BCI based on somatotopic organization but also that BCI control can be translated to different end effectors.
Intracortical MEA BCI
To perform activities of daily living, one needs to be able to position the hand in space, orient the palm, and grasp an object. Nonhuman primate studies have shown that intracortical MEAs can capture natural movement-related information that can enable these movements. 20, 21 This study's research group demonstrated that a person with tetraplegia was able to rapidly achieve control of a state-of-the-art motorized prosthetic limb (Johns Hopkins University, Applied Physics Laboratory). 3 Two MEAs were implanted in the motor cortex based on presurgical functional mapping. The neural decoder, which translates the brain activity into movement commands for the arm, was trained while the subject observed motion of the sophisticated multiple DOF prosthetic arm (motorized prosthetic limb under automatic computer control). After 13 wks of training, robust 7D (3D translation, 3D orientation, 1D grasping) movements were performed routinely. These movements included reaching and grasping tasks, similar to many activities of daily living, which were carried out with coordination, skill, and speed approaching that of an able-bodied person. This BCI allowed the study participant to perform a wide variety of tasks including shaking hands, stacking cones, and eating ( Fig. 4 ).
Sensation
Ultimately, the goal is to restore function to the entire upper limb. The loss of proprioception and tactile cues will make it more challenging for people to take advantage of neuroprosthetic technology designed to restore movement such as functional electrical stimulation as well as external assistive technology such as exoskeletons and robotic manipulators. Proprioception is generally considered to be crucially involved in the learning and control of motor action, and loss of proprioception can have a significant effect on a person's ability to move without visual input. 22, 23 Tactile feedback will be required to allow participants to manipulate compliant or fragile objects, to operate the BCI with limited or obscured vision, and to feel the sensation of performing a movement such as a handshake. Motorized prosthetics, as shown in Figure 2 , are equipped with sensors that detect tactile and proprioceptive information. It may be possible to transmit this information to the BCI user through stimulation of the nervous system.
The Dorsal Root Ganglion: An Ideal Target
The dorsal root ganglion (DRG) has many advantages, a site for recording neural signals and stimulating, when appropriate. 24Y27 Although there are many alternative sites to consider, the DRG (and adjacent dorsal roots) are the only structures where primary afferent (PA) neurons can be accessed in isolation from other neurons or fiber tracts. Because most PA neurons from an entire limb are grouped into approximately 2Y4 adjacent DRGs, they provide a compact target for accessing the complete set of PA neurons for the limb. Experiments have been performed to record simultaneously from large numbers of neurons in DRG and S1 during passive movement of the hindlimb. Modulated activity of a single DRG neuron and a single S1 neuron during passive movement demonstrates firing rates for both neurons that covary strongly with the ankle joint angle, demonstrating that these neurons may encode proprioceptive information for the ankle.
Applications of BCI in Stroke
There are a number of possible applications of BCI in the population with stroke. 28 First and most desirable would be to use BCI as a means to maximize neuroplasticity during the recovery phase. BCI can provide a high level of biofeedback and could be used, through both stimulation and demonstration of recording, to train different areas of the brain to compensate for function compromised by the initial stroke. This would require a temporary implantation, and therefore, potential complications related to long-term neural recording would be avoided.
If functional recovery could not be achieved via neuroplasticity, another option would be direct control of the affected limb using a long-term implant. The BCI signal and decoder could be used to simulate the patient's own muscles using functional electrical stimulation. Alternatively, the BCI could control an exoskeleton or a robotic arm, as pictured in Figure 2 . The BCI signal could come from an unimpaired portion of the impacted hemisphere. Alternatively, the BCI signal could be derived from the hemisphere ipsilateral to the impacted arm. Recent work has shown that bilateral control can be obtained from a single hemisphere. These findings also indicate that ipsilateral control could be obtained from the intact hemisphere. Finally, BCI could be used in conjunction with the stem cells and robotic techniques described earlier in this document. This possibility is described in the following section.
INTERSECTIONS
Although exciting possibilities for patients exist with each of the three modalities discussed, the best chance for success likely exists by combining these interventions. One can envision a future where a patient who has neurologic deficit related to a stroke is initially treated with stem cells. The stem cells reduce inflammation and seed the infarcted area with the cell types needed for repair. At the same time, as the surgery is done to inject the stem cells, BCI electrode is implanted. The BCI electrode's purpose is 2-fold: record signals from existing cells that can be used to provide biofeedback, thus maximizing neuroplasticity. In addition, once the stem cells are ready, they can be given a trigger toward appropriate differentiation and to make connections by the signal provided by the BCI implant. During this entire process, the patient will be undergoing robotic rehabilitation, which will maximize neuroplasticity and then provide the training needed to increase the use of the stem cells. The robotics is also documenting progress at a fine level so that plateaus in gains are noted and investigated. As this imaginary future illustrates, the modalities are complementary, which in the end might offer this study's patients the best recovery.
BARRIERS
Each of the approaches discussed previously face considerable barriers to clinical translation. A common barrier for all is the cost of research and treatment. Cutting-edge approaches, such as those discussed, require considerable research investment. In each area, research has been ongoing for years, yet only in the robotics realm has there been any penetration into more routine clinical practice and a business model that seems profitable. Interestingly, what has driven the use of robotics is likely marketing related and has less to do with proven outcomes. In the United States, providing robotic therapy does not allow for extra billing but may differentiate one institution from another and therefore attract patients. In the stem cell and BCI-related areas, the hurdles are higher for translation as the intervention is invasive and will have an absolute requirement for a reimbursement model to be successful. The authors strongly feel that investment in all three areas will lead to better outcomes for individuals with stroke and many other disorders.
CONCLUSIONS
Robots provide a method for providing welldefined, reproducible therapeutic exercise in a potentially labor-saving fashion. Advantages of robots compared with dose-matched human therapy for the delivery of exercise therapy remain intriguing but still unproven. Despite the promise of robots to deliver exercise therapy, use of these devices in clinical centers remains relatively low. There are a number of important barriers to broader adoption that need to be overcome to expand robotic use, with perhaps the most important ones being economic. Further advances in robotic technology, coupled with new delivery and reimbursement models, may be needed to fully overcome these barriers.
Our current understanding of the potential mechanism by which cell therapy improves outcome after stroke is limited. It is likely that stem cells have multiple mechanisms of action, and further research is necessary to define the optimal route of administration, timing of treatment, and number of cells for each cell type. Chronic stroke presents additional challenges. Innovative solutions will be needed involving scaffolds to allow multiple differentiated cell types to replace or repair irreversibly injured brain tissue. 29 Endogenous neural stem cells reside in the subventricular zone and are capable of migrating to the site of brain injury. However, the contribution of these cells to brain repair seems to be limited. As the scientists' knowledge of epigenetics evolves, it may be possible to enhance this process through modification of the microenvironment and targeted differentiation and integration. 30 Researchers are now in the earliest stages of cell therapy, and the promise of this therapeutic approach seems bright.
Finally, in the BCI area, tremendous breakthroughs have occurred related to achieving control with multiple DOFs. However, before this work translates to the clinical setting, work needs to be done to improve the long-term viability of implants. In addition, integrating sensory information into the motor control must be achieved to obtain the highest DOF, such as would be needed to operate a dexterous hand. Further study is needed to achieve these goals and to fully understand the possible interactions between BCI and recovery from stroke.
Advances in each area are likely to profoundly change the way clinicians treat patients with stroke in the future, and the use of all three modalities likely holds the most promise.
